Published date: 25 November 2021
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Pharmaceutical products - 33600000
Various medicinal products - 33690000
Location of contract
England
Value of contract
£3,185,000,000
Procurement reference
CF-0426000D0O000000rwimUAA1
Published date
25 November 2021
Closing date
3 September 2021
Closing time
1pm
Contract start date
1 January 2022
Contract end date
31 March 2024
Contract type
Supply contract
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
No
Contract is suitable for VCSEs?
No
Description
NHS Framework Agreement for the supply of Direct Oral Anticoagulants (DOACs) for the NHS in England. Also known as Novel Oral Anticoagulants (NOACs).
Period of Framework: 01/01/2022 - 31/03/2024 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 39 months)
Award information
Awarded date
15 November 2021
Contract start date
1 January 2022
Contract end date
31 March 2024
Total value of contract
£3,185,000,000
This contract was awarded to 3 suppliers.
Bristol Myers Squibb
Address
, Uxbridge, UB8 1DH
Reference
None
Supplier is SME?
No
Supplier is VCSE?
No
Bayer Ltd
Address
, Reading, RG2 6AD
Reference
None
Supplier is SME?
No
Supplier is VCSE?
No
Daiichi Sankyo UK Ltd
Address
, Uxbridge, UB8 1DH
Reference
None
Supplier is SME?
No
Supplier is VCSE?
No
About the buyer
Contact name
Strategic Category Management Team
Address
80 London Road
London
SE1 6LH
UK
Share this notice
Closing: 3 September 2021, 1pm
All content is available under the
